Changchun Hi-Tech announced that recently, its holding subsidiary Jinsai Pharmaceutical received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the application for registration of domestically produced drugs for injectable GenSci 136 was accepted. The drug is used to treat systemic lupus erythematosus. Previously, clinical trial applications for the drug to treat other conditions had been approved by the National Drug Administration or the US Food and Drug Administration. If the clinical trial application progresses smoothly, it will help the company expand its business and optimize the product structure, etc., but there is uncertainty about the follow-up process and results.

Changchun Hi-Tech announced that recently, its holding subsidiary Jinsai Pharmaceutical received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the application for registration of domestically produced drugs for injectable GenSci 136 was accepted. The drug is used to treat systemic lupus erythematosus. Previously, clinical trial applications for the drug to treat other conditions had been approved by the National Drug Administration or the US Food and Drug Administration. If the clinical trial application progresses smoothly, it will help the company expand its business and optimize the product structure, etc., but there is uncertainty about the follow-up process and results.